Pharmafile Logo
Pharmafocus logo
Advanced Search
pfizer_brussels

Pfizer sues Texas agency over leak of drug prices

November 21, 2016
Medical Communications, Sales and Marketing Drug pricing, Pfizer, US, texas

Pfizer has sued Texas’ Health and Human Services Commission, after it claimed the agency violated state and federal law by …

News
dna-163466

China conducts first gene-editing human trial

November 21, 2016
Research and Development, Sales and Marketing China, DNA, cas9, crispr

China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject, suffering from metastatic lung cancer. This …

News
gsk_wall

GSK 18 months ahead of the game with three-drug inhaler

November 21, 2016
Medical Communications, Sales and Marketing GSK, Innoviva, chronic obstructive pulmonary disease

GlaxoSmithKline, alongside its partner Innoviva, have filed a regulatory submission with the FDA for its treatment for chronic obstructive pulmonary …

News
teva_copy

Teva’s drug to replace chemotherapy in acute leukaemia

November 21, 2016
Medical Communications, Sales and Marketing Teva, chemotherapy, first line, first-line, leukaemia

Teva Pharmaceutical announced that their drug Trisenox has been given approval from the European Commission to become the first line …

News
novartis_hq_day

Novartis in $665 million deal for Selexys

November 21, 2016
Sales and Marketing Novartis, SelG1, selexys

Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …

News
clinical_trial

GSK/J&J release how their drug measures up against Humira

November 18, 2016
Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …

News
valeant

Former Valeant executive and Philidor CEO charged with fraud

November 18, 2016
Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud

Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …

News
humacao_exterior

NICE thumbs up for BMS leukaemia treatment

November 18, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia

Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …

News
twitter_phone

New healthcare app aims to improve patient adherence

November 17, 2016
Medical Communications, Sales and Marketing Echo, app, patient adherence, smartphone

The newly released app, named Echo, was developed by former Apple executive Dr Sai Lakshmi and former LloydsPharmacy executive Stephen …

News
flag_of_japan_

Japan to slash Opdivo costs by 50%

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo

Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …

News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …

News
nice_reception

NICE rules Shire’s Onivyde not cost effective

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …

News
images

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …

News

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …

News
placebo

Surprising number of parents agree to use of placebos in children

November 16, 2016
Medical Communications, Research and Development Placebo, children

A study by Boston Children’s Hospital found that parents recognised that placebos are a vital part of research and that …

News
shutterstock_292920209

Real world evidence: a reality check for pharma?

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence

Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …

Feature
msd

Powerful new data for MSD’s bladder cancer drug stops trial early

November 16, 2016
Research and Development MSD, pembrolizumab

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …

News

Abbott-St. Jude $25 billion deal close to clearance

November 16, 2016
Research and Development, Sales and Marketing Abbott, St. Jude, acquisition

EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …

News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016
Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …

News
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026